Acellular Pertussis Vaccine Components

Approved acellular pertussis vaccines (aP) contain purified components from Bordetella pertussis, designed to reduce side effects compared to whole-cell vaccines.

Analyzing Vaccine Antigen Requirements

The composition of aP vaccines focuses on specific, immunogenic antigens. Let's evaluate the options:

• Option 1: Incorrect. While inactivated pertussis toxin (PT) is a key component, specifying "at least 3 IU" isn't the primary defining characteristic, and exact quantities can vary.
• Option 2: Correct. Approved aP vaccines typically contain a combination of purified antigens. Common examples include inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN). Therefore, containing at least 3 such pathogenic antigens is a standard requirement.
• Option 3: Incorrect. The efficacy comparison between aP and whole-cell pertussis vaccines is complex. While aP vaccines offer improved safety, claims of superior efficacy over whole-cell vaccines are debated and not universally accepted.
• Option 4: Incorrect. While nonfimbrial proteins like PT and FHA are included, stating their presence as a mandatory component is less precise than specifying the required number of key pathogenic antigens. Not all nonfimbrial proteins are necessarily included in every formulation.

Conclusion on Vaccine Composition

The most accurate statement regarding approved acellular pertussis vaccines is that they are formulated with a specific set of purified antigens. Containing a minimum of three key pathogenic antigens ensures the vaccine targets critical virulence factors of the bacteria while maintaining a favorable safety profile.